Input 2018.11.14 03:07
SK Bioscience has signed a licensing agreement to apply 'cell culture vaccine production technology' applied to the world's first 4-cell culture flu vaccine, Skyshell, to Sanofi Pasteur, a global vaccine leader. The technology transfer and licensing agreement with Sanofi Pasteur is up to $ 155 million, making it the largest ever export of vaccine technology in Korea.
SK Bioscience's cell culture flu vaccine production technology is based on the fact that the production process is quick and efficient using animal cells unlike the conventional method.
SK Zoster, the second vaccine of SK Bioscience, which is licensed for marketing in the world, is on the market at the same time. Cumulative sales of SkyJooster reached only 20 billion won in the first half of the year. Currently, some countries in Southeast Asia, including Thailand, are in the process of issuing licenses in accordance with the country registration requirements of SkyJooster.
In September, after approval of the shipment of the chicken pox vaccine 'Sky Barrisela' to the country, it started to supply it as a domestic disease and clinic. We are also participating in overseas bidding market.